Overview

Candidate Pre Phase 1 Phase 2 Phase 3

Leronlimab
(PRO 140)

Pre-Clinical Phase completed
Phase 1 completed
Phase 2 completed
Phase 3 in progress

Leronlimab (PRO 140)

Leronlimab PRO 140 is a fully humanized monoclonal antibody which is a cellular targeting CCR5 entry antagonist recently acquired from Progenics Pharmaceuticals.

Read more about leronlimab (PRO 140) ...